Cargando…

Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature

OBJECTIVE: Serous tubal intraepithelial carcinoma (STIC) is a precursor lesion of pelvic high-grade serous carcinoma (HGSC). Information on treatment and outcome of isolated STIC is rare. Therefore, we reviewed systematically the published literature to determine the incidence of subsequent HGSC in...

Descripción completa

Detalles Bibliográficos
Autores principales: Linz, Valerie Catherine, Löwe, Amelie, van der Ven, Josche, Hasenburg, Annette, Battista, Marco Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472545/
https://www.ncbi.nlm.nih.gov/pubmed/36119503
http://dx.doi.org/10.3389/fonc.2022.951292
_version_ 1784789325139935232
author Linz, Valerie Catherine
Löwe, Amelie
van der Ven, Josche
Hasenburg, Annette
Battista, Marco Johannes
author_facet Linz, Valerie Catherine
Löwe, Amelie
van der Ven, Josche
Hasenburg, Annette
Battista, Marco Johannes
author_sort Linz, Valerie Catherine
collection PubMed
description OBJECTIVE: Serous tubal intraepithelial carcinoma (STIC) is a precursor lesion of pelvic high-grade serous carcinoma (HGSC). Information on treatment and outcome of isolated STIC is rare. Therefore, we reviewed systematically the published literature to determine the incidence of subsequent HGSC in the high- and low-risk population and to summarize the current diagnostic and therapeutic options. METHODS: A systematic review of the literature was conducted in MEDLINE-Ovid, Cochrane Library and Web of Science of articles published from February 2006 to July 2021. Patients with an isolated STIC diagnosis and clinical follow-up were included. Study exclusion criteria for review were the presence of synchronous gynaecological cancer and/or concurrent non-gynaecological malignancies. RESULTS: 3031 abstracts were screened. 112 isolated STIC patients out of 21 publications were included in our analysis with a pooled median follow-up of 36 (interquartile range (IQR): 25.3-84) months. 71.4% of the patients had peritoneal washings (negative: 62.5%, positive: 8%, atypic cells: 0.9%). Surgical staging was performed in 28.6% of all STICs and did not show any malignancies. 14 out of 112 (12.5%) patients received adjuvant chemotherapy with Carboplatin and Paclitaxel. Eight (7.1%) patients developed a recurrence 42.5 (IQR: 33-72) months after isolated STIC diagnosis. Cumulative incidence of HGSC after five (ten) years was 10.5% (21.6%). Recurrence occurred only in BRCA1 carriers (seven out of eight patients, one patient with unknown BRCA status). CONCLUSION: The rate of HGSC after an isolated STIC diagnosis was 7.1% with a cumulative incidence of 10.5% (21.6%) after five (ten) years. HGSC was only observed in BRCA1 carriers. The role of adjuvant therapy and routine surveillance remains unclear, however, intense surveillance up to ten years is necessary. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD42021278340.
format Online
Article
Text
id pubmed-9472545
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94725452022-09-15 Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature Linz, Valerie Catherine Löwe, Amelie van der Ven, Josche Hasenburg, Annette Battista, Marco Johannes Front Oncol Oncology OBJECTIVE: Serous tubal intraepithelial carcinoma (STIC) is a precursor lesion of pelvic high-grade serous carcinoma (HGSC). Information on treatment and outcome of isolated STIC is rare. Therefore, we reviewed systematically the published literature to determine the incidence of subsequent HGSC in the high- and low-risk population and to summarize the current diagnostic and therapeutic options. METHODS: A systematic review of the literature was conducted in MEDLINE-Ovid, Cochrane Library and Web of Science of articles published from February 2006 to July 2021. Patients with an isolated STIC diagnosis and clinical follow-up were included. Study exclusion criteria for review were the presence of synchronous gynaecological cancer and/or concurrent non-gynaecological malignancies. RESULTS: 3031 abstracts were screened. 112 isolated STIC patients out of 21 publications were included in our analysis with a pooled median follow-up of 36 (interquartile range (IQR): 25.3-84) months. 71.4% of the patients had peritoneal washings (negative: 62.5%, positive: 8%, atypic cells: 0.9%). Surgical staging was performed in 28.6% of all STICs and did not show any malignancies. 14 out of 112 (12.5%) patients received adjuvant chemotherapy with Carboplatin and Paclitaxel. Eight (7.1%) patients developed a recurrence 42.5 (IQR: 33-72) months after isolated STIC diagnosis. Cumulative incidence of HGSC after five (ten) years was 10.5% (21.6%). Recurrence occurred only in BRCA1 carriers (seven out of eight patients, one patient with unknown BRCA status). CONCLUSION: The rate of HGSC after an isolated STIC diagnosis was 7.1% with a cumulative incidence of 10.5% (21.6%) after five (ten) years. HGSC was only observed in BRCA1 carriers. The role of adjuvant therapy and routine surveillance remains unclear, however, intense surveillance up to ten years is necessary. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD42021278340. Frontiers Media S.A. 2022-08-31 /pmc/articles/PMC9472545/ /pubmed/36119503 http://dx.doi.org/10.3389/fonc.2022.951292 Text en Copyright © 2022 Linz, Löwe, van der Ven, Hasenburg and Battista https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Linz, Valerie Catherine
Löwe, Amelie
van der Ven, Josche
Hasenburg, Annette
Battista, Marco Johannes
Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature
title Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature
title_full Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature
title_fullStr Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature
title_full_unstemmed Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature
title_short Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature
title_sort incidence of pelvic high-grade serous carcinoma after isolated stic diagnosis: a systematic review of the literature
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472545/
https://www.ncbi.nlm.nih.gov/pubmed/36119503
http://dx.doi.org/10.3389/fonc.2022.951292
work_keys_str_mv AT linzvaleriecatherine incidenceofpelvichighgradeserouscarcinomaafterisolatedsticdiagnosisasystematicreviewoftheliterature
AT loweamelie incidenceofpelvichighgradeserouscarcinomaafterisolatedsticdiagnosisasystematicreviewoftheliterature
AT vandervenjosche incidenceofpelvichighgradeserouscarcinomaafterisolatedsticdiagnosisasystematicreviewoftheliterature
AT hasenburgannette incidenceofpelvichighgradeserouscarcinomaafterisolatedsticdiagnosisasystematicreviewoftheliterature
AT battistamarcojohannes incidenceofpelvichighgradeserouscarcinomaafterisolatedsticdiagnosisasystematicreviewoftheliterature